The Role of Alpha Particles in Radiotheranostics
Alpha particles provide precise cancer treatment by delivering high-energy radiation, targeting tumour cells while sparing healthy tissue.
The Role of Alpha Particles in Radiotheranostics Read Post »
Prostate Cancer Therapy
Prostate cancer is the second most common cancer in men, affecting millions worldwide. Over the past few years, significant advancements have been made in understanding the disease’s biology, leading to improved diagnostic methods and more effective therapies. This article provides an overview of the current state of prostate cancer therapy, touching on both traditional and emerging treatments and the challenges faced in providing personalised care for patients.
Conventional Treatments
- Surgery: Radical prostatectomy is a common surgical treatment for prostate cancer involving the removal of the entire prostate gland and surrounding tissues. While this approach has been effective in many cases, it can lead to complications such as urinary incontinence and erectile dysfunction.
- Radiation Therapy: External beam radiation therapy (EBRT) and brachytherapy are widely used radiation treatments. EBRT targets the prostate gland with high-energy X-rays, while brachytherapy involves the placement of radioactive seeds directly into the prostate tissue. Unfortunately, both methods can cause side effects, including bowel and urinary problems.
- Hormone Therapy: Androgen deprivation therapy (ADT) is used to lower the levels of male hormones (androgens) that stimulate prostate cancer growth. ADT can be administered through injections, oral medications, or surgical castration. Side effects may include hot flashes, fatigue, and loss of libido.
Emerging Treatments
- Immunotherapy is a promising treatment modality that uses the patient’s immune system to fight cancer cells. Checkpoint inhibitors, such as pembrolizumab and nivolumab, have shown promising results in clinical trials, extending survival rates in certain cases. Another approach is the use of therapeutic cancer vaccines, which stimulate the immune system to recognise and attack cancer cells.
- Targeted Therapy results from advances in genomic profiling identifying specific genetic mutations driving prostate cancer. Targeted therapies, such as PARP and PI3K inhibitors, are designed to exploit these genetic vulnerabilities and disrupt cancer cell growth.
- Focal therapy aims to target and destroy only the cancerous tissue within the prostate, preserving the healthy surrounding tissue. High-intensity focused ultrasound (HIFU) and cryotherapy are examples of focal therapy methods that minimise the risk of side effects like incontinence and erectile dysfunction.
Challenges in Personalised Care
Despite the advancements in prostate cancer therapy, challenges remain in providing personalised care for patients. The heterogeneity of the disease, variable treatment responses, and resistance mechanisms complicate the selection of optimal therapies. Moreover, access to cutting-edge treatments can be limited due to high costs and availability in certain regions.
[wpseo_breadcrumbs]
Tactile Imaging: Transforming Diagnostic Medicine Through the Sense of Touch
The Science Behind Tactile Imaging Medical diagnostics have seen remarkable advancements over the years, with imaging technologies playing a pivotal
Tactile Imaging: Transforming Diagnostic Medicine Through the Sense of Touch Read Post »
The Role of Targeted Alpha Radionuclide Therapy in Modern Oncology
Targeted Alpha Radionuclide Therapy precisely delivers potent alpha particles to tumors, maximising efficacy while sparing healthy tissues.
The Role of Targeted Alpha Radionuclide Therapy in Modern Oncology Read Post »
Copper-67 SARbisPSMA New Frontier in Prostate Cancer Treatment
Copper-67 SARbisPSMA offers new hope in targeting and treating prostate cancer with precision and effectiveness.
Copper-67 SARbisPSMA New Frontier in Prostate Cancer Treatment Read Post »
Revolutionising Cancer Care: The Promise and Challenges of Radiotheranostics
Radiotheranostics merges diagnostics and therapy, offering targeted cancer treatment amidst challenges like high costs and need for specialised facilities.
Revolutionising Cancer Care: The Promise and Challenges of Radiotheranostics Read Post »
Actinium-225 Rosopatamab: A Breakthrough in Metastatic Prostate Cancer Treatment
225Ac-Rosopatamab, targeting metastatic prostate cancer, combines monoclonal antibodies with alpha radiation, showing promise in early trials.
Actinium-225 Rosopatamab: A Breakthrough in Metastatic Prostate Cancer Treatment Read Post »
Actinium-225 PSMA-617: Revolutionising Prostate Cancer Treatment
225Ac-PSMA-617 revolutionises prostate cancer treatment, offering targeted, effective therapy with promising clinical trial results.
Actinium-225 PSMA-617: Revolutionising Prostate Cancer Treatment Read Post »
Actinium-225 FPI-2265: A Promising Alpha Emitter for Metastatic Castration-Resistant Prostate Cancer Treatment
225Ac-FPI-2265, targeting PSMA, shows promise in treating advanced prostate cancer in the TATCIST clinical trial.
Actinium-225 DOTAZOL Alpharadiotherapy in Bone Diseases with a Focus on Prostate Cancer Treatment
225Ac-DOTAZOL enhances 177Lu-radiotherapy in bone diseases, particularly effective in prostate cancer, as shown in preclinical studies.
Actinium-225 DOTA-YS5: A Novel CD46-Targeted Radiopharmaceutical for Prostate Cancer Therapy
225Ac-DOTA-YS5 targets CD46 in prostate cancer, promising precision and effectiveness in therapy.
Lighting the Way in Healthcare: The Transformative Role of Lasers in Medicine
Lasers in medicine offer revolutionary precision and versatility, significantly advancing healthcare through diverse, minimally invasive applications.
Lighting the Way in Healthcare: The Transformative Role of Lasers in Medicine Read Post »
Lutetium Radiopharmaceuticals in Medicine: A Comprehensive Review
Lutetium radiopharmaceuticals significantly advance targeted cancer treatment and diagnostic capabilities.
Lutetium Radiopharmaceuticals in Medicine: A Comprehensive Review Read Post »
Posluma (Flotufolastat F-18): A Revolution in Precision Imaging and Theranostic Approaches for Prostate Cancer
Posluma (Flotufolastat F-18) offers precise PET imaging for detecting PSMA-positive prostate cancer lesions.
Radium-223 Dichloride (Xofigo): Targeted Alpha Therapy for Castration-Resistant Prostate Cancer with Bone Metastases
Radium-223 dichloride, a targeted alpha therapy, effectively treats castration-resistant prostate cancer with bone metastases, improving patients’ overall survival.
Pluvicto (Lutetium-177 Vipivotide Tetraxetan): A Focused Assault on Metastatic Castration-Resistant Prostate Cancer
Lutetium-177 Vipivotide Tetraxetan – Pluvicto: Radiopharmaceutical for targeted cancer therapy. Innovative, promising, precise, advanced, therapeutic.
Targeting Metastatic Castration Resistant Prostate Cancer: The Promising Role of Lutetium-177 PSMA Radioligand Therapy
Prostate cancer’s global impact persists; mCRPC, demanding advanced strategies, finds hope in 177Lu-PSMA targeted radioligand therapy.
Fluorine-18 Piflufolastat: An Innovative Approach to Prostate Cancer Imaging
Fluorine-18 Piflufolastat, a novel radiotracer, enables precise imaging of prostate cancer, enhancing diagnostic accuracy and facilitating personalied, targeted treatment approaches.
Fluorine-18 Piflufolastat: An Innovative Approach to Prostate Cancer Imaging Read Post »
Fluorine-18 Flucicovine (Axumin) PET Imaging: A Game Changer in Prostate Cancer Detection and Management
Fluorine-18 Flucicovine (Axumin) improves prostate cancer detection, enabling accurate diagnosis and targeted treatments with PET imaging.
Inaugural editorial review: nuclear medicine, diagnostic imaging and therapy
Topics on PET imaging, automated radiosynthesis, breast cancer, prostate cancer therapy and ultrasound.
Inaugural editorial review: nuclear medicine, diagnostic imaging and therapy Read Post »